New asthma drug could let patients ditch daily steroid pills
NCT ID NCT05274815
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called tezepelumab in 305 adults with severe asthma who were already taking daily steroid pills. The goal was to see if tezepelumab could help them safely reduce or stop their oral steroids without losing asthma control. Participants received tezepelumab injections every 4 weeks, and researchers tracked how many could lower their steroid dose over 28 and 52 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tezepelumab
What this could lead to
If successful, this could offer a way for people with severe asthma to reduce or stop taking daily oral steroids, lowering the risk of steroid side effects.
What could go wrong
This is a single-arm study without a placebo group, so results may be less reliable. It also focuses on steroid reduction, not a cure, and long-term safety is still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Newport Beach, California, 92663, United States
-
Research Site
Newark, Delaware, 19713, United States
-
Research Site
Loxahatchee Groves, Florida, 33470, United States
-
Research Site
Ann Arbor, Michigan, 48109, United States
-
Research Site
Toms River, New Jersey, 08755, United States
-
Research Site
The Bronx, New York, 10467, United States
-
Research Site
DuBois, Pennsylvania, 15801, United States
-
Research Site
Buenos Aires, C1121ABE, Argentina
-
Research Site
CABA, 1426, Argentina
-
Research Site
CABA, C1012AAR, Argentina
-
Research Site
Mendoza, M5500GHB, Argentina
-
Research Site
Monte Grande, 1842, Argentina
-
Research Site
Pilar, 1629, Argentina
-
Research Site
Quilmes, B1878FNR, Argentina
-
Research Site
Ranelagh, 1886, Argentina
-
Research Site
Rosario, 2000, Argentina
-
Research Site
San Fernando, B1646EBJ, Argentina
-
Research Site
San Juan Bautista, 1888, Argentina
-
Research Site
San Miguel de Tucumán, 4000, Argentina
-
Research Site
Brussels (Woluwé-St-Lambert), 1200, Belgium
-
Research Site
Erpent, 5101, Belgium
-
Research Site
Ghent, 9000, Belgium
-
Research Site
Liège, 4000, Belgium
-
Research Site
Haskovo, 6305, Bulgaria
-
Research Site
Razgrad, 7200, Bulgaria
-
Research Site
Sofia, 1142, Bulgaria
-
Research Site
Sofia, 1431, Bulgaria
-
Research Site
Sofia, 5000, Bulgaria
-
Research Site
Velika Tarnovo, 5250, Bulgaria
-
Research Site
Antony, 92160, France
-
Research Site
Bordeaux, 33076, France
-
Research Site
Brest, 29609, France
-
Research Site
Lyon, 69004, France
-
Research Site
Marseille, 13915, France
-
Research Site
Montpellier, France
-
Research Site
Nantes, 44000, France
-
Research Site
Nice, 06000, France
-
Research Site
Berlin, 12203, Germany
-
Research Site
Darmstadt, 64283, Germany
-
Research Site
Fürstenwalde, 15517, Germany
-
Research Site
Mainz, 55128, Germany
-
Research Site
Reinfeld (Holstein), 23858, Germany
-
Research Site
Daugavpils, LV-5410, Latvia
-
Research Site
Daugavpils, LV-5417, Latvia
-
Research Site
Jūrmala, LV-2015, Latvia
-
Research Site
Riga, LV-1011, Latvia
-
Research Site
Riga, LV1002, Latvia
-
Research Site
Riga, LV1010, Latvia
-
Research Site
Valmiera, LV-4201, Latvia
-
Research Site
Chihuahua City, 31000, Mexico
-
Research Site
Chihuahua City, 31200, Mexico
-
Research Site
Guadalajara, 44100, Mexico
-
Research Site
Monterrey, 64360, Mexico
-
Research Site
Bychawa, 23100, Poland
-
Research Site
Chmielnik, 26-020, Poland
-
Research Site
Gdansk, 80-952, Poland
-
Research Site
Krakow, 31-011, Poland
-
Research Site
Lodz, 92-213, Poland
-
Research Site
Ostrowiec Świętokrzyski, 27-400, Poland
-
Research Site
Sosnowiec, 41-200, Poland
-
Research Site
Wroclaw, 50-044, Poland
-
Research Site
Wroclaw, 53-301, Poland
-
Research Site
Wroclaw, 54-239, Poland
-
Research Site
Badalona, 08916, Spain
-
Research Site
Barcelona, 8035, Spain
-
Research Site
Madrid, 28041, Spain
-
Research Site
Oviedo, 33011, Spain
-
Research Site
Santa Cruz de Tenerife, 38010, Spain
-
Research Site
Santander, 39008, Spain
-
Research Site
Seville, 41009, Spain
-
Research Site
Belfast, BT97AB, United Kingdom
-
Research Site
Bradford, BD9 6RJ, United Kingdom
-
Research Site
LE3 9QP, United Kingdom
-
Research Site
London, SE1 7EH, United Kingdom
-
Research Site
London, SW3 6HP, United Kingdom
-
Research Site
Nottingham, NG5 1PB, United Kingdom
-
Research Site
Portsmouth, PO6 3LY, United Kingdom